| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ratings for Zoetis (NYSE:ZTS) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $225.25, a high estimate of $260.00, and a low estimate of $195.00. Surpassing the previous average price target of $218.75, the current average has increased by 2.97%.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Zoetis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jonathan Block | Stifel | Lowers | Buy | $195.00 | $215.00 |
| David Westenberg | Piper Sandler | Raises | Overweight | $220.00 | $215.00 |
| Balaji Prasad | Barclays | Raises | Overweight | $260.00 | $255.00 |
| Nathan Rich | Goldman Sachs | Raises | Buy | $226.00 | $190.00 |
To gain a panoramic view of Zoetis's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Zoetis analyst ratings.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Zoetis showcased positive performance, achieving a revenue growth rate of 8.48% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Zoetis's net margin is impressive, surpassing industry averages. With a net margin of 23.72%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Zoetis's ROE stands out, surpassing industry averages. With an impressive ROE of 10.42%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Zoetis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.7%, the company showcases efficient use of assets and strong financial health.
Debt Management: Zoetis's debt-to-equity ratio surpasses industry norms, standing at 1.35. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ZTS
